These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 14678996)

  • 1. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
    Dormond O; Foletti A; Paroz C; Rüegg C
    Nat Med; 2001 Sep; 7(9):1041-7. PubMed ID: 11533708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
    Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
    Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.
    Jiang WG; Hiscox SE; Parr C; Martin TA; Matsumoto K; Nakamura T; Mansel RE
    Clin Cancer Res; 1999 Nov; 5(11):3695-703. PubMed ID: 10589789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
    Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
    Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
    Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
    Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor beta2 inhibition of hepatocyte growth factor-induced endothelial proliferation and migration.
    Manganini M; Maier JA
    Oncogene; 2000 Jan; 19(1):124-33. PubMed ID: 10644987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor.
    Brzozowski T; Konturek PC; Konturek SJ; Pajdo R; Schuppan D; Drozdowicz D; Ptak A; Pawlik M; Nakamura T; Hahn EG
    J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):751-73. PubMed ID: 11192947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal anti-inflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production.
    Bamba H; Ota S; Kato A; Matsuzaki F
    Biochem Biophys Res Commun; 1998 Apr; 245(2):567-71. PubMed ID: 9571196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
    Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
    Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
    Elder DJ; Halton DE; Hague A; Paraskeva C
    Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives.
    Dermond O; Rüegg C
    Drug Resist Updat; 2001 Oct; 4(5):314-21. PubMed ID: 11991685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Li RC; Gherardi E; Zhao G; Watson N; Sasisekharan R; Fan TP
    Circulation; 2003 Jun; 107(23):2955-61. PubMed ID: 12782568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
    Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA
    J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
    Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
    Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.